FEATURES OF THE COURSE OF COVID-19 IN HOSPITALIZED PATIENTS DEPENDING ON THE TYPE OF VACCINE RECEIVED AND THE VACCINATION COURSE
DOI:
https://doi.org/10.11603/1681-2727.2025.1.15152Keywords:
coronavirus disease 2019, SARS-CoV-2, severity, vaccination, mRNA vaccines, inactivated vaccinesAbstract
According to the literature vaccination is currently an effective method in preventing severe COVID-19, hospitalization, and death from it. Research on the effectiveness of approved vaccines is important for the development of public health strategies and measures to protect the population from COVID-19.
The aim: to analyze the possible impact of vaccination (the type of vaccine received and the vaccination course) on the severity of coronavirus disease 2019 in hospitalized vaccinated patients who contracted COVID-19 for the first time.
Materials and methods: the study included 129 hospitalized vaccinated patients with laboratory-confirmed SARS-CoV-2 infection. According to the severity of the disease, patients were divided into two groups: moderate and severe. According to the type of vaccine received, two comparison groups were identified: patients who received mRNA vaccines (Pfizer/Moderna) and patients who received an inactivated vaccine (CoronaVac). All patients were also divided into those who received a full (2 doses) or partial (1 dose) course of vaccination.
Results: The majority of patients who were vaccinated had moderately severe disease (p=0.0001). In fact, in the structure of all vaccinated patients, regardless of the severity of the course, the group of those who received vaccination with the inactivated CoronaVac vaccine significantly prevailed (p=0.0004).
References
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. Jama, 324(8), 782-793. doi: 10.1001/jama.2020.12839. DOI: https://doi.org/10.1001/jama.2020.12839
Statement on the fifteenth meeting of the IHR. (2005). Emergency Committee on the COVID-19 pandemic. www.who.int. Retrieved from https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
Berksel, E., Aykac, A., Akdur, D., & Suer, K. (2023). Frequency of Developing COVID-19 Pneumonia in Patients Who Were Vaccinated Double-Dose CoronaVac: Data of the Pandemic Authorized Hospital in Northern Cyprus. Ethiopian Journal of Health Sciences, 33(5), 725-734. doi: 10.4314/ejhs.v33i5.2. DOI: https://doi.org/10.4314/ejhs.v33i5.2
COVID-19 Vaccines with WHO Emergency Use Listing. extranet.who.int. Retrieved from https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., ... & Lopez Bernal, J. (2022). Duration of protection against mild and severe disease by Covid-19 vaccines. New England Journal of Medicine, 386(4), 340-350. doi: 10.1056/NEJMoa2115481. DOI: https://doi.org/10.1056/NEJMoa2115481
Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., ... & Ramsay, M. (2021). Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med, 385(7), 585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21. Erratum in: N Engl J Med. 2023 Feb 16;388(7):672. doi: 10.1056/NEJMx210015. DOI: https://doi.org/10.1056/NEJMoa2108891
Zhou, Z., Zhu, Y., & Chu, M. (2022). Role of COVID-19 vaccines in SARS-CoV-2 variants. Frontiers in immunology, 13, 898192. doi: 10.3389/fimmu.2022.898192. DOI: https://doi.org/10.3389/fimmu.2022.898192
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Gruber, W. C. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine, 383(27), 2603-2615. doi: 10.1056/NEJMoa2034577. DOI: https://doi.org/10.1056/NEJMoa2034577
Vilches, T. N., Zhang, K., Van Exan, R., Langley, J. M., & Moghadas, S. M. (2021). Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. Vaccine, 39(17), 2360-2365. doi: 10.1016/j.vaccine.2021.03.058. DOI: https://doi.org/10.1016/j.vaccine.2021.03.058
Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., ... & Araos, R. (2021). Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New England Journal of Medicine, 385(10), 875-884. doi: 10.1056/NEJMoa2107715. DOI: https://doi.org/10.1056/NEJMoa2107715
Singh, P., Anand, A., Rana, S., Kumar, A., Goel, P., Kumar, S., ... & Singh, H. (2024). Impact of COVID-19 vaccination: a global perspective. Frontiers in Public Health, 11, 1272961. doi: 10.3389/fpubh.2023. DOI: https://doi.org/10.3389/fpubh.2023.1272961
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 О. В. Ряба, І. А. Анастасій
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal Infectious Disease (Infektsiini Khvoroby) allows the author(s) to hold the copyright without registration
Users can use, reuse and build upon the material published in the journal but only for non-commercial purposes
This journal is available through Creative Commons (CC) License BY-NC "Attribution-NonCommercial" 4.0
